WO2012103510A3 - Advanced prime and boost vacinne - Google Patents

Advanced prime and boost vacinne Download PDF

Info

Publication number
WO2012103510A3
WO2012103510A3 PCT/US2012/023015 US2012023015W WO2012103510A3 WO 2012103510 A3 WO2012103510 A3 WO 2012103510A3 US 2012023015 W US2012023015 W US 2012023015W WO 2012103510 A3 WO2012103510 A3 WO 2012103510A3
Authority
WO
WIPO (PCT)
Prior art keywords
vaccines
host
boost
vacinne
prime
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/023015
Other languages
French (fr)
Other versions
WO2012103510A8 (en
WO2012103510A2 (en
Inventor
Boro Dropulic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lentigen Corp
Original Assignee
Lentigen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lentigen Corp filed Critical Lentigen Corp
Priority to EP12739439.3A priority Critical patent/EP2667893A2/en
Priority to CA2825032A priority patent/CA2825032A1/en
Priority to RU2013139565/10A priority patent/RU2013139565A/en
Priority to US13/981,173 priority patent/US20130302368A1/en
Publication of WO2012103510A2 publication Critical patent/WO2012103510A2/en
Publication of WO2012103510A8 publication Critical patent/WO2012103510A8/en
Anticipated expiration legal-status Critical
Publication of WO2012103510A3 publication Critical patent/WO2012103510A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

This invention relates to vaccines and in particular to the combination of non- integrating, replication-incompetent retroviral vectors (NIV) with virus-like particle (VLP) vaccines to induce an immune response in an animal host following administration to the host. This combination results in a novel vaccine strategy for delivering priming and boost doses, wherein an effective amount of an NIV is administered to the host, followed by an effective amount of a VLP. The concept can be broadly applied to infectious disease vaccines and also to cancer vaccines.
PCT/US2012/023015 2011-01-27 2012-01-27 Advanced prime and boost vacinne Ceased WO2012103510A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP12739439.3A EP2667893A2 (en) 2011-01-27 2012-01-27 Advanced prime and boost vacinne
CA2825032A CA2825032A1 (en) 2011-01-27 2012-01-27 Advanced prime and boost vaccine
RU2013139565/10A RU2013139565A (en) 2011-01-27 2012-01-27 ADVANCED PRIMER AND BOOSTER VACCINE
US13/981,173 US20130302368A1 (en) 2011-01-27 2012-01-27 Advanced Prime and Boost Vaccine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161436828P 2011-01-27 2011-01-27
US61/436,828 2011-01-27

Publications (3)

Publication Number Publication Date
WO2012103510A2 WO2012103510A2 (en) 2012-08-02
WO2012103510A8 WO2012103510A8 (en) 2012-09-20
WO2012103510A3 true WO2012103510A3 (en) 2015-06-11

Family

ID=46581436

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/023015 Ceased WO2012103510A2 (en) 2011-01-27 2012-01-27 Advanced prime and boost vacinne

Country Status (5)

Country Link
US (1) US20130302368A1 (en)
EP (1) EP2667893A2 (en)
CA (1) CA2825032A1 (en)
RU (1) RU2013139565A (en)
WO (1) WO2012103510A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA027236B1 (en) 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
RU2705556C2 (en) 2012-12-21 2019-11-07 Келверум Инк. Non-replicating virus-derived particles and use thereof
EP3031923A1 (en) * 2014-12-11 2016-06-15 Institut Pasteur Lentiviral vector-based japanese encephalitis immunogenic composition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010105251A2 (en) * 2009-03-13 2010-09-16 Lentigen Corporation Non-integrating retroviral vector vaccines

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080408A (en) * 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
EP2055316A1 (en) * 2003-09-09 2009-05-06 VIRxSYS Corporation Lentivirus vector-based approaches for generating an immune response to HIV in humans

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010105251A2 (en) * 2009-03-13 2010-09-16 Lentigen Corporation Non-integrating retroviral vector vaccines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARTINEZ ET AL.: "Protection by SIV VLP DNA prime/protein boost following mucosal SIV challenge is markedly enhanced by IL -12/GM-CSF co-administration", JOURNAL OF MEDICAL PRIMATOLOGY, vol. 31, 2002, pages 217 - 227 *

Also Published As

Publication number Publication date
WO2012103510A8 (en) 2012-09-20
EP2667893A2 (en) 2013-12-04
US20130302368A1 (en) 2013-11-14
RU2013139565A (en) 2015-03-10
CA2825032A1 (en) 2012-08-02
WO2012103510A2 (en) 2012-08-02

Similar Documents

Publication Publication Date Title
CN106659777A8 (en) IMMUNOGENIC COMPOSITION product
JP2016539946A5 (en)
WO2013006842A3 (en) Self-replicating rna prime - protein boost vaccines
TR201908199T4 (en) Vaccines against HPV.
PE20140845A1 (en) PARENTERAL FORMULATIONS OF VACCINES AGAINST NOROVIRUSES
EP4494650A3 (en) Vaccine compositions having improved stability and immunogenicity
JP2012184264A5 (en)
WO2013098655A3 (en) Vaccines directed against human enteroviruses
MX2015008847A (en) Influenza virus immunogenic compositions and uses thereof.
FI4023249T3 (en) Nucleic acid vaccines
EP4421177A3 (en) Prefusion rsv f proteins and their use
AU2013367751A8 (en) Nasal influenza vaccine composition
EP4056198A3 (en) Outer membrane vesicles
JP2016513638A5 (en)
WO2010037027A3 (en) Immunization of avians by mucosal administration of non-replicating vectored vaccines
HK1208355A1 (en) Universal influenza vaccine based on heterologous multiple m2e proteins
NZ630831A (en) Compositions and methods for administration of vaccines against dengue virus
WO2016011422A8 (en) Manufacturing of multi-dose injection ready dendritic cell vaccines and combination therapy for blocking her2 and her3
PH12014501388A1 (en) A recombinant koi herpesvirus (khv) and vaccine for the prevention of a disease caused by khv
MX2013013228A (en) Virus-like particles and process for preparing same.
WO2012103510A3 (en) Advanced prime and boost vacinne
JP2016514672A5 (en)
WO2010045431A3 (en) Dry powder formulations, vaccines and methods
WO2013055326A3 (en) Vaccines for human papilloma virus and methods for using the same
DK201370530A (en) Salmonid alphavirus vaccine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12739439

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2825032

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 13981173

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012739439

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2013139565

Country of ref document: RU

Kind code of ref document: A